Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience

SIMPLE SUMMARY: Metastatic melanoma patients derive unprecedented benefit from immunotherapy, and some of them are even considered cured. Currently, there is no consensus on the safety nor on the timing of treatment discontinuation in this population. This is a real-world study on 106 advanced melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Asher, Nethanel, Israeli-Weller, Noa, Shapira-Frommer, Ronnie, Ben-Betzalel, Guy, Schachter, Jacob, Meirson, Tomer, Markel, Gal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234591/
https://www.ncbi.nlm.nih.gov/pubmed/34203061
http://dx.doi.org/10.3390/cancers13123074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234591/
https://www.ncbi.nlm.nih.gov/pubmed/34203061
http://dx.doi.org/10.3390/cancers13123074

Ejemplares similares